Try our beta test site
29 studies found for:    pralatrexate
Show Display Options
Rank Status Study
1 Completed Erlotinib in Combination With Pralatrexate in Advanced Malignancies
Conditions: Advanced Cancers;   Solid Tumors
Interventions: Drug: Erlotinib;   Drug: Pralatrexate
2 Recruiting A Dose-Finding Study of Folotyn® (Pralatrexate Injection) Plus CHOP With Peripheral T-Cell Lymphoma (PTCL)
Condition: Peripheral T-Cell Lymphoma (PTCL)
Intervention: Drug: Pralatrexate Injection
3 Terminated Study of Pralatrexate Versus Observation Following CHOP-based Chemotherapy in Previously Undiagnosed Peripheral T-cell Lymphoma Patients
Condition: Peripheral T-cell Lymphoma
Intervention: Drug: Pralatrexate Injection
4 Completed Pralatrexate and Oxaliplatin in Treating Patients With Unresectable or Metastatic Esophageal, Stomach, or Gastroesophageal Junction Cancer
Conditions: Adenocarcinoma of the Gastroesophageal Junction;   Esophageal Undifferentiated Carcinoma;   Gastric Adenocarcinoma;   Gastric Squamous Cell Carcinoma;   Recurrent Esophageal Adenocarcinoma;   Recurrent Esophageal Squamous Cell Carcinoma;   Recurrent Gastric Carcinoma;   Stage IIIB Esophageal Adenocarcinoma;   Stage IIIB Esophageal Squamous Cell Carcinoma;   Stage IIIB Gastric Cancer;   Stage IIIC Esophageal Adenocarcinoma;   Stage IIIC Esophageal Squamous Cell Carcinoma;   Stage IIIC Gastric Cancer;   Stage IV Esophageal Adenocarcinoma;   Stage IV Esophageal Squamous Cell Carcinoma;   Stage IV Gastric Cancer;   Undifferentiated Gastric Carcinoma
Interventions: Other: Laboratory Biomarker Analysis;   Drug: Oxaliplatin;   Drug: Pralatrexate
5 Completed Phase I Bortezomib (VELCADE) in Combo With Pralatrexate in Relapsed/Refractory MM
Condition: Multiple Myeloma
Interventions: Drug: velcade;   Drug: Pralatrexate
6 Recruiting Pralatrexate + Romidepsin in Relapsed/Refractory Lymphoid Malignancies
Conditions: Lymphoid Malignancies;   Multiple Myeloma;   Lymphoma;   Hodgkin Lymphoma;   Non-hodgkin Lymphoma
Interventions: Drug: Pralatrexate;   Drug: Romidepsin
7 Completed Study of Pralatrexate in Patients With Relapsed or Refractory Cutaneous T-cell Lymphoma
Condition: Cutaneous T-cell Lymphoma
Interventions: Drug: Pralatrexate Injection;   Dietary Supplement: Vitamin B12;   Dietary Supplement: Folic Acid
8 Completed
Has Results
Study of Pralatrexate With Vitamin B12 and Folic Acid Supplementation for Previously Treated Recurrent or Metastatic Head and Neck Squamous Cell Cancer (HNSCC)
Condition: Head and Neck Cancer
Intervention: Drug: Pralatrexate With Vitamin B12 and Folic Acid
9 Completed
Has Results
Study of Pralatrexate With Vitamin B12 and Folic Acid in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma
Condition: Peripheral T-cell Lymphoma
Intervention: Drug: Pralatrexate Injection
10 Completed
Has Results
Study of Pralatrexate vs. Erlotinib for Non-Small Cell Lung Cancer After at Least 1 Prior Platinum-based Treatment
Condition: Non-small Cell Lung Cancer
Interventions: Drug: Pralatrexate;   Drug: Erlotinib;   Dietary Supplement: Vitamin B12;   Dietary Supplement: Folic Acid
11 Recruiting Phase 2, Single Arm, Open Label Study of Folotyn in Combination With Oral Leucovorin to Prevent or Reduce Mucositis in Patients With PTCL
Conditions: Relapsed Peripheral T-Cell Lymphoma;   Refractory Peripheral T-Cell Lymphoma
Interventions: Drug: Folotyn and Leucovorin;   Drug: Folic Acid;   Drug: Vitamin B12
12 Active, not recruiting Phase II of Carbo/Pralatrexate in Rec. Platinum-Sensitive Ovarian, Fallopian or Primary Peritoneal Cancer
Conditions: Ovarian Cancer;   Fallopian Tube Cancer;   Peritoneal Cancer
Interventions: Drug: carboplatin;   Drug: pralatrexate
13 Withdrawn Phase 1 Study of Fusilev to Prevent or Reduce Mucositis in Patients With Non-Hodgkin's Lymphoma Receiving Folotyn
Condition: Non Hodgkin's Lymphoma
Interventions: Drug: Fusilev;   Drug: Folotyn
14 Withdrawn Phase 1 Study of Fusilev® to Prevent or Reduce Mucositis in Patients With Non-Small Cell Lung Cancer Receiving Folotyn®
Condition: Non-Small Cell Lung Cancer
Interventions: Drug: Folotyn;   Drug: Fusilev
15 Completed Pralatrexate and Bexarotene in Patients With Relapsed or Refractory Cutaneous T-cell Lymphoma
Conditions: Cutaneous T-cell Lymphoma;   Mycosis Fungoides;   Sezary Syndrome;   Primary Cutaneous Anaplastic Large Cell Lymphoma
Interventions: Drug: Pralatrexate Injection;   Drug: Bexarotene Capsules;   Dietary Supplement: Vitamin B12;   Dietary Supplement: Folic Acid
16 Completed
Has Results
Study of Pralatrexate & Gemcitabine With B12 & Folic Acid to Treat Relapsed/Refractory Lymphoproliferative Malignancies
Conditions: Relapsed or Refractory Lymphoproliferative Malignancies;   Hodgkin's Lymphoma;   Peripheral T-cell Lymphoma;   B-cell Lymphoma;   Waldenstrom's Macroglobulinemia
Interventions: Drug: Pralatrexate Injection;   Drug: Gemcitabine Hydrochloride;   Dietary Supplement: Vitamin B12;   Dietary Supplement: Folic Acid
17 Completed Study of Pralatrexate to Treat Patients With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma
Condition: Lymphoma, B-Cell
Interventions: Drug: Pralatrexate Injection;   Dietary Supplement: Vitamin B12;   Dietary Supplement: Folic Acid
18 Completed
Has Results
Study of Pralatrexate to Treat Advanced or Metastatic Relapsed Transitional Cell Carcinoma of the Urinary Bladder
Conditions: Carcinoma, Transitional Cell;   Bladder Cancer;   Bladder Neoplasm
Interventions: Drug: Pralatrexate Injection;   Dietary Supplement: Vitamin B12;   Dietary Supplement: Folic Acid
19 Completed
Has Results
Study of Pralatrexate in Female Patients With Previously-treated Breast Cancer
Conditions: Breast Cancer;   Breast Tumors;   Neoplasms, Breast;   Cancer of the Breast;   Human Mammary Carcinoma
Interventions: Drug: Pralatrexate Injection;   Dietary Supplement: Vitamin B12;   Dietary Supplement: Folic Acid
20 Completed
Has Results
Pralatrexate and Docetaxel in Treating Patients With Stage IV Esophageal or Gastroesophageal Cancer Who Have Failed Platinum-Based Therapy
Conditions: Adenocarcinoma of the Esophagus;   Adenocarcinomas of the Gastroesophageal Junction;   Recurrent Esophageal Cancer;   Squamous Cell Carcinoma of the Esophagus;   Stage IV Esophageal Cancer
Interventions: Drug: pralatrexate;   Drug: docetaxel;   Radiation: fludeoxyglucose F 18;   Procedure: positron emission tomography

   Previous Page Studies Shown (1-20) Next Page (21-29) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.